BRAF‐V600E expression correlates with ameloblastoma aggressiveness
Eduardo R Fregnani, Danyel E da Cruz Perez, Oslei Paes de Almeida, Felipe Paiva Fonseca, Fernando A Soares, Gilberto Castro‐Junior, Fábio A Alves
ARTIGO
Inglês
Agradecimentos: This research was supported by grants from the São Paulo State Research Foundation (FAPESP/Brazil).
Abstract: The aim of this study was to investigate whether the expression of BRAF-V600E determines an aggressive clinical and molecular presentation of ameloblastoma. Methods and results Ninety-three cases of solid ameloblastomas were arranged in a 1.0-mm tissue microarray (TMA) block....
Ver mais
Abstract: The aim of this study was to investigate whether the expression of BRAF-V600E determines an aggressive clinical and molecular presentation of ameloblastoma. Methods and results Ninety-three cases of solid ameloblastomas were arranged in a 1.0-mm tissue microarray (TMA) block. Immunohistochemistry against a large panel of cytokeratins (CK), epidermal growth factor receptor (EGFR), parathyroid hormone-related peptide (PTHrP), syndecan-1, Ki67, p53 and BRAF-V600E were performed. Clinicopathological parameters, including sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic pattern, vestibular/lingual and basal cortical plates disruption and follow-up data, were obtained from patients' medical records. Immunoexpression of BRAF-V600E was investigated in 73 cases that remained available in TMA sections. Our results indicated that 46.6% (34 cases) demonstrated cytoplasm positivity (six weak and 28 strong positivity). BRAF-V600E expression was associated significantly with the expression of CK8 (P = 0.00077), CK16 (P = 0.05), PTHrP (P = 0.0082) and p53 (P = 0.0087). Additionally, a significant association was seen with the presence of recurrences (P = 0.0008), multilocular radiographic appearance (P = 0.044) and disruption of basal bone cortical (P = 0.05). Univariate analysis showed that BRAF-positive cases (P = 0.001), EGFR-negative/weak positive cases (P = 0.03) and multilocular tumours (P = 0.04) had a significantly lower disease-free survival rate, but these parameters were not considered independent prognostic factors in the multivariate analysis (P > 0.05). Conclusions Our findings suggest an association of BRAF-V600E with parameters of a more aggressive behaviour of ameloblastoma, supporting the future use of BRAF inhibitors for targeted therapy of this neoplasm
Ver menos
FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP
Fechado
BRAF‐V600E expression correlates with ameloblastoma aggressiveness
Eduardo R Fregnani, Danyel E da Cruz Perez, Oslei Paes de Almeida, Felipe Paiva Fonseca, Fernando A Soares, Gilberto Castro‐Junior, Fábio A Alves
BRAF‐V600E expression correlates with ameloblastoma aggressiveness
Eduardo R Fregnani, Danyel E da Cruz Perez, Oslei Paes de Almeida, Felipe Paiva Fonseca, Fernando A Soares, Gilberto Castro‐Junior, Fábio A Alves
Fontes
|
Histopathology Vol. 70, no. 3 (Feb., 2017), p. 473-484 |